Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
2160 participants
INTERVENTIONAL
2025-03-21
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study objectives are as follows: (1) To assess the non-inferiority of soy-maize-sorghum (SMS-) RUTF and soy-based (S-) RUTF on treatment recovery to standard RUTF; (2) To assess the superiority of SMS-RUTF and S- RUTF on post-recovery relapse compared to standard RUTF; (3) To assess the costs of a treatment course of SMS-RUTF, S-RUTF, and standard RUTF; (4) To assess the effect of SMS-RUTF and S-RUTF on microbiome composition and intestinal inflammation
The investigators will conduct a facility-based, individually randomized controlled trial with three arms allocated in a 1:1:1 allocation ratio in 30 health facilities (Centre de Santé et Promotion Sociale \[CSPS\]) in Burkina Faso. The investigators will randomize 1080 children with MAM and 1080 children with uncomplicated SAM 6-59 months of age to receive treatment with one of the following RUTFs: (1) standard of care, milk- and peanut-based RUTF (control group); (2) SMS-RUTF free of milk and peanuts and high in fiber (intervention 1); or (3) S-RUTF free of milk and peanuts (intervention 2). Children will be enrolled upon presentation to facilities for MAM or uncomplicated SAM treatment. Follow up visits will be weekly during treatment for SAM children and bi-weekly during treatment for MAM children, and monthly for 3 months following discharge from treatment. The primary study outcomes include, among others, anthropometric recovery at discharge (a non-inferiority analysis) and relapse to MAM or SAM within the 3 months following recovery (a superiority analysis). The investigators will employ an activity-based micro-costing approach to collect cost data on the direct and indirect medical costs, opportunity costs to caregivers, personnel, and overheads associated with outpatient MAM or SAM treatment. Fecal samples will be collected from children at a subset of facilities (5 facilities, \~60 children per treatment arm), at enrollment (initiation of treatment), discharge from treatment, and 3-months post-discharge.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of an Alternative Protocol in the Management of Acute Malnutrition
NCT06792370
Treating Moderate Malnutrition in 6-24 Months Old Children
NCT01115647
Modified Dosage for Moderate Acute Malnutrition (MODAM-MAM)
NCT06056089
Effectiveness and Cost-Effectiveness of Four Formulations of Food Supplements for the Prevention of Wasting and Stunting in Burkina Faso
NCT02071563
Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children
NCT01634009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard RUTF
This is the control arm of the trial, in which children will receive the standard RUTF product for treatment of acute malnutrition
Standard RUTF
This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
Soy-based RUTF
This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-based RUTF
Soy-based RUTF
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
Soy-maize-sorghum-based RUTF
This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-maize-sorghum-based RUTF
Soy-maize-sorghum-based RUTF
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Soy-based RUTF
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
Soy-maize-sorghum-based RUTF
This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
Standard RUTF
This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* MUAC \< 12.5 cm, or WLZ/WHZ \< -2
* Absence of clinical complications or nutritional edema
* Pass the appetite test
* Accompanied by caregiver or legal guardian
* Caregiver or legal guardian consents to participate
Exclusion Criteria
* Known allergy to any of the ingredients in the RUTF products
* Already enrolled in MAM or SAM treatment program
* Presence of physical abnormalities that make measurement of anthropometry impossible
* Caregiver has intention to move out of the study area within the next 6 months
* Children referred from in-patient facilities to continue in ambulatory care
6 Months
59 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AFRICSante
UNKNOWN
Institut de Recherche en Sciences de la Sante, Burkina Faso
OTHER_GOV
International Food Policy Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laeticia Toe
Role: PRINCIPAL_INVESTIGATOR
Institut de Recherche en Sciences de la Santé
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health centers localted in the region of Hauts-Bassins
Bobo-Dioulasso, , Burkina Faso
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-RUTF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.